CD274 and neoplasm: Considering the increasing appreciation of the role played by tumor-cell intrinsic cues in shaping the immunobiology of the tumor microenvironment [18], we extended our analyses to PD-L1 expression, i.e., the biomarker used to assign NSCLC patients to immune checkpoint blockade-based therapies.